YCC receives $175k research grant from Breast Cancer Research Foundation

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Yale Cancer Center has received a one-year, $175,000 research grant from the Breast Cancer Research Foundation to study reducing re-excisions for breast conserving therapy for women following surgery for breast cancer.

Principal investigator of the grant, Mehra Golshan, joins three other YCC BCRF funded researchers: Melinda Irwin, Lajos Pusztai, and David Rimm.

This grant reflects the need to find ways to reduce unnecessary re-excisions during their treatment that leads to delay in initiation of adjuvant therapy, increase in costs, negative psychological impact, more women choosing mastectomy and higher infection rates,” Golshan, deputy chief medical officer for Surgical Services at Smilow Cancer Hospital and YCC, and interim director of the Breast Center at Smilow Cancer Hospital, said in a statement.

During breast conserving surgery, the need for re-excision occurs between 15-25% of time. When removing a breast tumor, surgeons strive for clean margins. That means targeting not only the tumor, but also excising the surrounding border of tissue. Margins are clean if no cancer cells are found at the outer edge of that tissue.

Table of Contents

YOU MAY BE INTERESTED IN

Just consider for a minute if this was the first year of running your lab, if you were on the job market as a physician or scientist right now, if you were a resident contemplating a career in cancer research after fellowship, if you were a graduate student or postdoc, if you were an undergraduate or a technician who was looking toward graduate school.
The immune system can be a powerful tool to control cancer. Immune cells within our body detect cancer cells and release payloads that kill them. Transformative science in the last decade has led to the development of therapies that enhance the ability of our immune cells to carry out this function. These therapies, including checkpoint blockade and CAR-T cells, have been lifesaving for many patients that before had untreatable cancer. But, sadly, a majority of patients with advanced solid tumors still succumb to their disease. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login